

Heather A Jacene

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1037068/publications.pdf>

Version: 2024-02-01

65
papers

7,056
citations

279798

23
h-index

144013

57
g-index

66
all docs

66
docs citations

66
times ranked

9064
citing authors

#	ARTICLE	IF	CITATIONS
1	From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors. <i>Journal of Nuclear Medicine</i> , 2009, 50, 122S-150S.	5.0	3,047
2	Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors. <i>New England Journal of Medicine</i> , 2017, 376, 125-135.	27.0	2,206
3	Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. <i>Blood</i> , 2016, 128, 2489-2496.	1.4	370
4	Cancer Immunotherapy: Imaging Assessment of Novel Treatment Response Patterns and Immune-related Adverse Events. <i>Radiographics</i> , 2015, 35, 424-437.	3.3	161
5	Imaging of Pelvic Malignancies with In-Line FDG PET-CT: Case Examples and Common Pitfalls of FDG PET. <i>Radiographics</i> , 2005, 25, 1031-1043.	3.3	143
6	Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: A study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's Cancer Center. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 592-599.	1.2	93
7	Comparison of ⁹⁰ Y-Ibritumomab Tiuxetan and ¹³¹ I-Tositumomab in Clinical Practice. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1767-1776.	5.0	81
8	Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. <i>Blood</i> , 2012, 119, 4129-4132.	1.4	67
9	¹⁸ F-FDG PET/CT for Monitoring the Response of Lymphoma to Radioimmunotherapy. <i>Journal of Nuclear Medicine</i> , 2009, 50, 8-17.	5.0	66
10	Assessment of Interobserver Reproducibility in Quantitative ¹⁸ F-FDG PET and CT Measurements of Tumor Response to Therapy. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1760-1769.	5.0	65
11	Comparison of Residence Time Estimation Methods for Radioimmunotherapy Dosimetry and Treatment Planning Monte Carlo Simulation Studies. <i>IEEE Transactions on Medical Imaging</i> , 2008, 27, 521-530.	8.9	48
12	Effects of pegfilgrastim on normal biodistribution of ¹⁸ F-FDG: preclinical and clinical studies. <i>Journal of Nuclear Medicine</i> , 2006, 47, 950-6.	5.0	43
13	Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. <i>European Journal of Cancer</i> , 2019, 114, 107-116.	2.8	42
14	Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e289-e298.	1.9	40
15	Gynecologic Oncologic Imaging With PET/CT. <i>Seminars in Nuclear Medicine</i> , 2014, 44, 461-478.	4.6	33
16	Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns. <i>Journal of Nuclear Medicine</i> , 2021, 62, 23S-35S.	5.0	32
17	Inflammatory breast cancer and development of brain metastases: risk factors and outcomes. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 225-232.	2.5	29
18	Systemic Immune Response to Vaccination on FDG-PET/CT. <i>Nuclear Medicine and Molecular Imaging</i> , 2016, 50, 358-361.	1.0	28

#	ARTICLE	IF	CITATIONS
19	PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up. <i>Seminars in Nuclear Medicine</i> , 2018, 48, 37-49.	4.6	28
20	Lymphadenopathy Resulting From Acute Hepatitis C Infection Mimicking Metastatic Breast Carcinoma on FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2006, 31, 379-381.	1.3	27
21	Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management. <i>Annals of Surgical Oncology</i> , 2015, 22, 2483-2491.	1.5	26
22	The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 2563-2569.	1.5	26
23	Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. <i>Melanoma Research</i> , 2018, 28, 605-610.	1.2	24
24	End-Therapy Positron Emission Tomography for Treatment Response Assessment in Follicular Lymphoma: A Systematic Review and Meta-analysis. <i>Clinical Cancer Research</i> , 2013, 19, 6566-6577.	7.0	21
25	Radionuclide Therapy for Osseous Metastases in Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 66-80.	4.6	21
26	Scalene muscle uptake: a potential pitfall in head and neck PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 89-94.	6.4	20
27	Guidance on ¹⁷⁷ Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division. <i>Journal of Nuclear Medicine Technology</i> , 2018, 46, 237-244.	0.8	19
28	Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice. <i>Journal of Nuclear Medicine</i> , 2021, 62, 60S-72S.	5.0	19
29	F-18 FDG PET/CT in Acute Respiratory Distress Syndrome: A Case Report. <i>Clinical Nuclear Medicine</i> , 2004, 29, 786-788.	1.3	16
30	Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 383-390.	2.5	16
31	Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer: Risk Factors and Practical Considerations. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e919-e926.	1.9	14
32	Metabolic characterization of inflammatory breast cancer (IBC) with baseline FDG-PET/CT: Relationship with histopathology, hormone receptor status, and pathologic response after neoadjuvant chemotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 1105-1105.	1.6	14
33	Extraprostatic Uptake of ¹⁸ F-Fluciclovine: Differentiation of Nonprostatic Neoplasms From Metastatic Prostate Cancer. <i>American Journal of Roentgenology</i> , 2020, 214, 641-648.	2.2	13
34	Cancer Imaging at the Crossroads of Precision Medicine: Perspective From an Academic Imaging Department in a Comprehensive Cancer Center. <i>Journal of the American College of Radiology</i> , 2016, 13, 365-371.	1.8	12
35	Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma. <i>Molecular Imaging and Biology</i> , 2017, 19, 429-436.	2.6	12
36	Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?. <i>Journal of Clinical Oncology</i> , 2022, 40, 3011-3014.	1.6	12

#	ARTICLE	IF	CITATIONS
37	Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma. <i>PET Clinics</i> , 2015, 10, 207-225.	3.0	11
38	Quantitation of Cancer Treatment Response by 18F-FDG PET/CT: Multicenter Assessment of Measurement Variability. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1429-1434.	5.0	11
39	Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana-Farber Cancer Institute's Inflammatory Breast Cancer Program experience. <i>Breast Journal</i> , 2020, 26, 384-390.	1.0	10
40	Imaging Androgen Receptors in Breast Cancer with ¹⁸ F-Fluoro-5 α -Dihydrotestosterone PET: A Pilot Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 22-28.	5.0	10
41	SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma. <i>Endocrine-Related Cancer</i> , 2022, 29, 533-544.	3.1	9
42	Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin [®]) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels. <i>Cancers</i> , 2021, 13, 2828.	3.7	8
43	Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD cycles followed by FDG-PET/CT restaging and 20 Gy of involved-site radiotherapy. <i>Leukemia and Lymphoma</i> , 2018, 59, 1384-1390.	1.3	7
44	Phase I/II Dose-Escalation Study of Tositumomab and Iodine I 131 Tositumomab for Relapsed/Refractory Classical or Lymphocyte-Predominant Hodgkin's Lymphoma: Feasibility and Initial Safety. <i>Blood</i> , 2008, 112, 3059-3059.	1.4	7
45	2-deoxy-2-[F] fluoro-D-glucose uptake in intercostal respiratory muscles on positron emission tomography/computed tomography: smokers versus nonsmokers. <i>Molecular Imaging and Biology</i> , 2004, 6, 405-410.	2.6	6
46	Postradiation Changes in Tissues. <i>PET Clinics</i> , 2014, 9, 217-235.	3.0	6
47	Refractory myeloid sarcoma with a FIP1L1-PDGFR α rearrangement detected by clinical high throughput somatic sequencing. <i>Experimental Hematology and Oncology</i> , 2015, 4, 30.	5.0	6
48	Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Phase 2 Clinical Trials and Off-Trial Experience. <i>Blood</i> , 2018, 132, 145-145.	1.4	5
49	Evidence-Based Best Practices. <i>Clinical Nuclear Medicine</i> , 2021, 46, 569-570.	1.3	4
50	FDG PET for Assessment of Autologous Stem Cell Transplantation. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 380-391.	4.6	4
51	Surveillance Imaging in Patients With Endometrial Cancer in First Remission. <i>Current Problems in Diagnostic Radiology</i> , 2018, 47, 311-316.	1.4	3
52	Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade. <i>Clinical Breast Cancer</i> , 2019, 19, 146-155.	2.4	3
53	Dermal Lymphatic Invasion, Survival, and Time to Recurrence or Progression in Inflammatory Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 449-455.	1.3	3
54	PET Imaging for Hematologic Malignancies. <i>Radiologic Clinics of North America</i> , 2021, 59, 705-723.	1.8	3

#	ARTICLE	IF	CITATIONS
55	Correlation of 68Ga-DOTATATE uptake on PET/CT with pathologic features of cellular proliferation in neuroendocrine neoplasms. <i>Annals of Nuclear Medicine</i> , 2021, 35, 1066-1077.	2.2	2
56	Imaging for Radiation Planning in Breast Cancer. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 542-550.	4.6	2
57	MRI Changes in Breast Skin Following Preoperative Therapy for Patients with Inflammatory Breast Cancer. <i>Academic Radiology</i> , 2021, , .	2.5	1
58	Intercostal Brown Adipose Tissue on FDG PET/CT. <i>American Journal of Roentgenology</i> , 2021, 217, 1007-1007.	2.2	1
59	No delayed imaging or CCK administration is needed in most cases when bowel excretion does not occur but gallbladder fills promptly. <i>Annals of Nuclear Medicine</i> , 2019, 33, 740-745.	2.2	0
60	Computed tomographic assessment of lean body mass in patients on selective androgen receptor modulator. <i>Clinical Imaging</i> , 2020, 59, 100-103.	1.5	0
61	Positron emission tomography/computed tomography to improve staging and restaging in Merkel cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8552-8552.	1.6	0
62	Clinical practice patterns of Radium-223 (R223) utilization and variables associated with completion of therapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16076-e16076.	1.6	0
63	2018 SNMMI Highlights Lecture: General Nuclear Medicine. <i>Journal of Nuclear Medicine</i> , 2018, 59, 7N-13N.	5.0	0
64	2019 SNMMI Highlights Lecture: General Nuclear Medicine and Molecular Imaging. <i>Journal of Nuclear Medicine</i> , 2019, 60, 13N-18N.	5.0	0
65	2020 SNMMI Highlights Lecture: General Nuclear Medicine and Molecular Imaging. <i>Journal of Nuclear Medicine</i> , 2020, 61, 17N-23N.	5.0	0